These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 36255625)

  • 1. Synthesis, Biochemical, and Cellular Evaluation of HDAC6 Targeting Proteolysis Targeting Chimeras.
    Darwish S; Heimburg T; Ridinger J; Herp D; Schmidt M; Romier C; Jung M; Oehme I; Sippl W
    Methods Mol Biol; 2023; 2589():179-193. PubMed ID: 36255625
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Solid-Phase Synthesis of Cereblon-Recruiting Selective Histone Deacetylase 6 Degraders (HDAC6 PROTACs) with Antileukemic Activity.
    Sinatra L; Yang J; Schliehe-Diecks J; Dienstbier N; Vogt M; Gebing P; Bachmann LM; Sönnichsen M; Lenz T; Stühler K; Schöler A; Borkhardt A; Bhatia S; Hansen FK
    J Med Chem; 2022 Dec; 65(24):16860-16878. PubMed ID: 36473103
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proteasomal Degradation of Zn-Dependent Hdacs: The E3-Ligases Implicated and the Designed Protacs That Enable Degradation.
    Márquez-Cantudo L; Ramos A; Coderch C; de Pascual-Teresa B
    Molecules; 2021 Sep; 26(18):. PubMed ID: 34577077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of histone deacetylase 3 (HDAC3)-specific PROTACs.
    Xiao Y; Wang J; Zhao LY; Chen X; Zheng G; Zhang X; Liao D
    Chem Commun (Camb); 2020 Aug; 56(68):9866-9869. PubMed ID: 32840532
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proteolysis-targeting chimeras (PROTACs) in cancer therapy.
    Li X; Pu W; Zheng Q; Ai M; Chen S; Peng Y
    Mol Cancer; 2022 Apr; 21(1):99. PubMed ID: 35410300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of Expression and Functions of Histone Deacetylase 6 (HDAC6).
    Li M; Zhuang Y; Shan B
    Methods Mol Biol; 2016; 1436():85-94. PubMed ID: 27246209
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Designing HDAC-PROTACs: lessons learned so far.
    Fischer F; Alves Avelar LA; Murray L; Kurz T
    Future Med Chem; 2022 Jan; 14(3):143-166. PubMed ID: 34951318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, Synthesis and Biological Characterization of Histone Deacetylase 8 (HDAC8) Proteolysis Targeting Chimeras (PROTACs) with Anti-Neuroblastoma Activity.
    Darwish S; Ghazy E; Heimburg T; Herp D; Zeyen P; Salem-Altintas R; Ridinger J; Robaa D; Schmidtkunz K; Erdmann F; Schmidt M; Romier C; Jung M; Oehme I; Sippl W
    Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35886887
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis.
    Li D; Marchenko ND; Moll UM
    Cell Death Differ; 2011 Dec; 18(12):1904-13. PubMed ID: 21637290
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cullin 3SPOP ubiquitin E3 ligase promotes the poly-ubiquitination and degradation of HDAC6.
    Tan Y; Ci Y; Dai X; Wu F; Guo J; Liu D; North BJ; Huo J; Zhang J
    Oncotarget; 2017 Jul; 8(29):47890-47901. PubMed ID: 28599312
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Application of PROTACs in Hematological Malignancies--Review].
    Jia YN; Mi YC
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Dec; 31(6):1921-1924. PubMed ID: 38071084
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induced protein degradation of histone deacetylases 3 (HDAC3) by proteolysis targeting chimera (PROTAC).
    Cao F; de Weerd S; Chen D; Zwinderman MRH; van der Wouden PE; Dekker FJ
    Eur J Med Chem; 2020 Dec; 208():112800. PubMed ID: 32971411
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proteolysis-targeting chimeras for targeting protein for degradation.
    Qi J; Zhang G
    Future Med Chem; 2019 Apr; 11(7):723-741. PubMed ID: 30706727
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Homo-PROTACs: bivalent small-molecule dimerizers of the VHL E3 ubiquitin ligase to induce self-degradation.
    Maniaci C; Hughes SJ; Testa A; Chen W; Lamont DJ; Rocha S; Alessi DR; Romeo R; Ciulli A
    Nat Commun; 2017 Oct; 8(1):830. PubMed ID: 29018234
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and Evaluation of Cereblon-Recruiting HaloPROTACs.
    Ody BK; Zhang J; Nelson SE; Xie Y; Liu R; Dodd CJ; Jacobs SE; Whitzel SL; Williams LA; Gozem S; Turlington M; Yin J
    Chembiochem; 2023 Nov; 24(21):e202300498. PubMed ID: 37625128
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The rise of covalent proteolysis targeting chimeras.
    Gabizon R; London N
    Curr Opin Chem Biol; 2021 Jun; 62():24-33. PubMed ID: 33549806
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HDAC6 at the intersection of autophagy, the ubiquitin-proteasome system and neurodegeneration.
    Pandey UB; Batlevi Y; Baehrecke EH; Taylor JP
    Autophagy; 2007; 3(6):643-5. PubMed ID: 17912024
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PROTACs: Novel approach for cancer breakdown by breaking proteins.
    Memon H; Patel BM
    Life Sci; 2022 Jul; 300():120577. PubMed ID: 35487303
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PROTACs: Current and Future Potential as a Precision Medicine Strategy to Combat Cancer.
    Rutherford KA; McManus KJ
    Mol Cancer Ther; 2024 Apr; 23(4):454-463. PubMed ID: 38205881
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ubiquitin proteasome system stress underlies synergistic killing of ovarian cancer cells by bortezomib and a novel HDAC6 inhibitor.
    Bazzaro M; Lin Z; Santillan A; Lee MK; Wang MC; Chan KC; Bristow RE; Mazitschek R; Bradner J; Roden RB
    Clin Cancer Res; 2008 Nov; 14(22):7340-7. PubMed ID: 19010849
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.